This year the dengue campaign is the responsibility of each jurisdiction. Specialists indicate the importance of preventing in the present, when the virus has not yet spread on a large scale, because doing so in the summer months would be starting to fight when the battle is lost. To the repellent and the waste, in 2024, fortunately, the vaccine will be added. One of the most controversial points is that the Japanese technology – called Qdenga – is recommended by different health authorities for those under 60 years of age. Unlike what happened with covid, the platform is not preferably indicated for older adults and that is why there are doubts about whether or not populations in this age range should be pricked..
In dialogue with Page 12, Daniel Hozborbiochemist and principal researcher at Conicet at the Institute of Biotechnology and Molecular Biology of La Plata, points out: “The point of vaccination against dengue in those over 60 is controversial because The clinical studies were first carried out in the population aged 4 to 16 years, and then complemented by a bridging study in older people, but without including those aged 60 or over. “There is progress in that.” However, he continues with the detail: “One of the main issues to pay attention to in vaccines is safety. In Argentina, there is some data that has even been shared at conferences that shows that It is safe for older children too.”.
In this sense, Mario Lozanovirologist at Conicet, points out: “Although we still do not have the results for people over 60, there are preliminary indications that indicate that there is no decrease in the immune response, that the protection is good as in adults and adolescents. It is a very safe vaccine, therefore, my recommendation for older people is that they get immunized“.
The effectiveness of the vaccine in preventing infection is around 80 percent and in protecting against severe disease is 90 percent, one year after vaccination. Contraindicated in pregnant women and immunosuppressed individuals, it is based on serotype 2 of the virus and genetic material from the rest (1, 3 and 4) is added with the aim of offering comprehensive protection against all forms of dengue that circulate in the planet.
In Argentina, as in other nations, the approval was made for people aged four and older, so it could be estimated, according to Hozbor, that those over 60 would be included. “The elderly population is not the priority on this occasion because in terms of incidence, that age group is not at the forefront.” Here it is worth distinguishing a concept: although there is less incidence in them (since the greatest number of cases were recorded in young adults), they do present more mortality because, as expected, they usually face comorbidities that increase the risk.
Consult a trusted doctor
In this framework, patient consultation with trusted health professionals will be key, because each case is specific and is evaluated comprehensively, taking into account previous history and clinical history. “If you consider that your patient should be inoculated, the recommendation is never out of place,” says Hozbor. In parallel, it is necessary for doctors to be aware of the latest scientific evidence available, to indicate whether it is necessary or not according to each person’s circumstances.. If they require it, an order is enough to be inoculated in pharmacies that supply it. Qdenga consists of a two-dose schedule that must be given three months apart. Each puncture costs around 98 thousand pesos and after the first, the body generates antibodies and considerable protection.
Vaccine centers, for example, offer payment and financing facilities. This is how they explain it on their site: “On the amount, the agreed discount is applied according to the medical coverage and you can pay in 3 interest-free installments through Mercado Pago. For private patients we offer a 20% discount by paying in cash, credit and debit card.” For its part, the province of Buenos Aires promotes immunization and, along these lines, for those who are affiliated with IOMA it provides a 30 percent discount and the application is free of charge.
Those who, in theory, should have priority in access to the vaccine are those who have already had dengue in the past. They are, for example, the residents of the provinces with uninterrupted transmission (northeast Argentina), as well as the northwest and central territories with high incidence.
The rules of the market
The National Immunization Commission (CoNaIn), in line with the recommendation that the provinces made in a more or less homogeneous manner, then begins the campaign for the smallest bands. Access to vaccines is limited in each jurisdiction, because since the dengue vaccine was not included in the mandatory schedule, the Nation does not guarantee its access.
This is in line with a health system that, during the libertarian administration, restricts more than what it includes. The apparent zero deficit policy also reaches sensitive areas, so that “every man for himself” translates into “every man for himself who has money.” The market and its rules that always favor them.
Beyond the fact that the vaccine is a fundamental prevention tool, there are also other instruments linked to waste. The female mosquito vector of dengue, the famous Aedes ageyptiplace the eggs on any object capable of accumulating water. In the summer, as the temperature and rainfall increase, the ideal scenario is created for the eggs to hatch and the larvae to emerge. These larvae will then be the insects that transmit the disease; They will be the messengers who, by biting someone who is sick, will be able to make someone who is not sick sick. Hence, eliminating any container that can accumulate water is a simple measure that actively involves all citizens. And it is one of the most effective in controlling the circulation of mosquitoes and, therefore, the spread of the disease.
[email protected]
Dengue Vaccination: A Dose of Reality
Welcome to the great dengue debate, where the stakes are high and the mosquitoes are higher! As this year’s dengue campaign shifts responsibilities onto individual jurisdictions (because apparently, it’s not enough to just dodge the dengue, we’ve got to fight it ourselves, too!), experts are urging everyone to take preventive measures before the viral party really kicks off in the summer months. It’s akin to putting on your sunscreen while you’re already roasting under the sun—better late than never gets a serious workout!
The Vaccine Dilemma
But, hold on! There’s a twist in our dengue saga. Enter the Qdenga vaccine—a cutting-edge Japanese marvel—proclaimed with much fanfare for everyone under 60. What’s that? Older folks have a bit of a concern over the whole “not being included in clinical trials” business? Who can blame them? After all, if there’s one thing stirring up confusion quicker than a mosquito can bite, it’s the age limits on vaccines.
According to Daniel Hozbor, a biochemist with a name that sounds like he could be a character in a sci-fi film, there’s a legitimate concern about vaccinating those over 60, primarily because the clinical studies kicked off in a much younger crowd—think kids aged 4 to 16. They later did some bridging studies on older people but, spoiler alert, they didn’t exactly invite the sixty-plus crowd to join the party. It’s like starting a book club and only inviting half your friends because the other half might get lost on the way!
Safety First!
But don’t panic just yet! Virologist Mario Lozano steps in saying it’s safe. Imagine a virologist swooping in like a cape-wearing superhero to save the day—kind of reassuring, isn’t it? He claims early signs show that older adults might respond just as well as younger ones. So, for the older generation, the call to arms is clear: Get that vaccine!
With effectiveness rates hitting about 80% for infection and a whopping 90% for severe disease, it sounds like the vaccine is the ticket to ride—if you can afford the 98,000 pesos for your two doses! And let’s not forget, access can be as restricted as a VIP area at a concert. You know, “No vaccine for you unless you’re in the right jurisdiction!”
Consult a Doctor? Absolutely!
If you’re scratching your head about whether to roll up your sleeve, experts say to consult a trusted doctor—because every situation is like a unique recipe: a pinch of history, a dash of previous conditions, and perhaps a squeeze of advice from your local health professional. It’s a buffet of options! And hopefully, one that won’t break the bank—at least some places are offering fancy payment plans. Because who doesn’t love a good installment plan on their health?
Market Madness
Now, a shout-out to the National Immunization Commission, which apparently aligns its campaign like a bad family gathering—everyone wants a piece of the pie but nobody can agree on who gets first dibs. And although the vaccine is crucial, let’s not forget our little winged friends—the female Aedes aegypti mosquitoes. They’re laying their eggs on any puddle of water they can find, throwing a party without any thought to the consequences. So, while we’re debating vaccine access, let’s clean up and toss out those water-collecting containers! Because one less breeding ground means one less chance to catch dengue, and more time enjoying the summer.
Sure, vaccines are a vital weapon in our fight against dengue, but community action is just as essential. It’s a team sport, folks! So, grab your neighbors and rally together against those pesky mosquitoes.
And there you have it: a wild ride through the dengue vaccination landscape—where age is just a number, confusion is an art, and safety is a priority. Stay vigilant, stay informed, and don’t forget your insect repellent!
**Interview: Insights on Dengue Vaccination with Biochemist Daniel Hozbor**
**Interviewer:** Welcome, Daniel Hozbor. Thank you for joining us to discuss the current dengue vaccination landscape. It’s been a hot topic, particularly the introduction of the Qdenga vaccine. Can you start by explaining why this year’s dengue campaign has shifted responsibilities to local jurisdictions?
**Daniel Hozbor:** Thank you for having me. The shift in responsibility to local jurisdictions is significant because it empowers communities to take proactive measures against dengue before it potentially spreads during the high-risk summer months. Acting early is crucial because late interventions can be too late; prevention is the key to controlling outbreaks.
**Interviewer:** Speaking of prevention, the Qdenga vaccine has generated quite a discussion, especially regarding its age recommendations. Can you elaborate on the concerns surrounding vaccine safety for those over 60?
**Daniel Hozbor:** Absolutely. The controversy stems from the fact that initial clinical trials for Qdenga focused on younger populations, specifically ages 4 to 16. While there were bridging studies for older adults, individuals over 60 were not included. This raises safety questions and concerns for older generations who may want to get vaccinated.
**Interviewer:** That makes sense. However, I understand there are indications that the vaccine might still be effective for older adults. What are those indications?
**Daniel Hozbor:** Yes, that’s right. Although definitive results for those over 60 are pending, preliminary data suggests that older adults do not show a decrease in immune response and can benefit from protection similar to that of younger individuals. Thus, my recommendation aligns with the growing consensus that older adults should consider getting the vaccine, emphasizing that safety remains a priority.
**Interviewer:** With effectiveness rates reportedly around 80% for infection and 90% for severe disease, this vaccine seems promising. However, the cost and accessibility are important factors. What can you tell us about that?
**Daniel Hozbor:** The vaccine does come at a significant cost—around 98,000 pesos for a two-dose schedule, which can be burdensome. However, it’s essential to highlight that some jurisdictions, like the province of Buenos Aires, are offering discounts and free vaccinations for certain populations. This initiative aims to encourage immunization, especially among those most at risk.
**Interviewer:** It seems like a layered issue, from affordability to age considerations. How important is consultation with healthcare professionals for potential vaccine recipients?
**Daniel Hozbor:** Consultation is crucial. Each individual’s health history is unique, and trusted healthcare professionals can provide tailored advice based on the latest scientific evidence available. If an individual is deemed a good candidate for vaccination, the recommendation to proceed will always be beneficial and timely.
**Interviewer:** while vaccination is a key tool, what other preventive measures should communities adopt to combat dengue?
**Daniel Hozbor:** Everyone can help control the dengue outbreak by maintaining clean environments. This includes eliminating standing water where the Aedes aegypti mosquito breeds. It can be as simple as removing containers that hold water. Public awareness and community involvement are critical for effective prevention.
**Interviewer:** Thank you, Daniel, for your insights. It seems that while the introduction of the Qdenga vaccine presents new options, ongoing awareness and community action remain fundamental in combating dengue.
**Daniel Hozbor:** Absolutely. Thank you for the discussion. It’s essential that we all work together for effective prevention and healthcare measures.
**Interviewer:** Thank you, Daniel, for your insights on dengue vaccination. Moving beyond just the vaccine, what holistic approaches should communities be taking to combat the dengue threat this summer?
**Daniel Hozbor:** Great question! Beyond vaccination, we need community participation to eliminate mosquito breeding sites. That’s the female *Aedes aegypti*, responsible for spreading dengue. Residents should regularly check their surroundings for items accumulating water, like old tires or buckets, and dispose of them. This proactive community engagement is essential. Along with vaccination efforts, it’s a powerful approach to limit both the spread of the virus and the number of cases.
**Interviewer:** This community action is crucial. Now, can you speak to the importance of consulting health professionals before getting vaccinated, especially for older adults?
**Daniel Hozbor:** Absolutely. It’s vital to consult trusted healthcare providers who can assess individual medical histories and risks. Each person’s situation is unique, and doctors are best equipped to recommend the vaccine based on their specific health conditions. We want to ensure the decision to vaccinate is informed and tailored to each individual’s circumstances.
**Interviewer:** Thank you, Daniel. As we wrap up, what’s your final message to the public regarding dengue prevention and the vaccine?
**Daniel Hozbor:** The key message is to stay informed and proactive. Engage in preventive measures, consider vaccination if eligible, and consult health professionals. Dengue is a manageable threat if we all take responsibility. Prevention and timely action can save lives, so let’s work together to protect our communities.
**Interviewer:** Thank you for your time, Daniel. Your insights are invaluable as we navigate this critical public health issue.